跳至主要内容
临床试验/DRKS00033359
DRKS00033359尚未招募不适用

Prospective German Real World Epidyolex® Beyond Seizure Study - PROGRESS - PROGRESS

Jazz Pharmaceuticals Germany GmbH0 个研究点目标入组 80 人开始时间: 2024年2月20日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
2 Years 至 one(—)
性别
All

入选标准

  • 1.Patients aged 2 years and older, diagnosed with LGS, DS, or TSC.
  • 2.The decision to prescribe Epidyolex® as an adjunctive therapy for seizures associated with LGS, DS, or TSC was entirely independent of including the patient in the study.
  • 3.Patient, or parent(s)/legal representative(s) must be willing and able to give informed consent/assent for participation in the study.

排除标准

  • 1.The patient is currently using or have used cannabis-based products (including recreational, medicinal cannabis, or any other cannabinoid-based products) within the 3 months prior to study entry, unless that has already been observed as part of this study.
  • 2.The patient who is already enrolled in any other Jazz-sponsored or funded study must not be enrolled. If a patient is enrolled in another Jazz-sponsored or funded study while they are under observation of the PROGRESS study, their participation in the PROGRESS study must be terminated.
  • 3. The patient has the indication LGS or DS and is receiving Epidyolex® not in
  • conjunction with clobazam, and therefore not according to SmPC.

研究者

相似试验